Although our findings underscore the value of Cyr61 as a biomarker, more prospective studies and clinical trials are warranted to better elucidate the role of Cyr61 in the onset and progression of PAD in T2DM patients. This evidence concerns the gene CCN1 and type 2 diabetes mellitus.